Unicycive Therapeutics (UNCY) Competitors $5.00 +0.29 (+6.16%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$5.03 +0.03 (+0.60%) As of 10/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. MREO, NMRA, ALEC, GALT, SCPH, TECX, ACB, JBIO, IMMP, and KYTXShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), Alector (ALEC), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), Tectonic Therapeutic (TECX), Aurora Cannabis (ACB), Jade Biosciences (JBIO), Prima BioMed (IMMP), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Mereo BioPharma Group Neumora Therapeutics Alector Galectin Therapeutics scPharmaceuticals Tectonic Therapeutic Aurora Cannabis Jade Biosciences Prima BioMed Kyverna Therapeutics Unicycive Therapeutics (NASDAQ:UNCY) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Does the media prefer UNCY or MREO? In the previous week, Mereo BioPharma Group had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Unicycive Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.43 beat Unicycive Therapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is UNCY or MREO more profitable? Mereo BioPharma Group's return on equity of -80.00% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -243.13% -119.46% Mereo BioPharma Group N/A -80.00%-66.94% Do analysts recommend UNCY or MREO? Unicycive Therapeutics currently has a consensus target price of $57.00, suggesting a potential upside of 1,040.00%. Mereo BioPharma Group has a consensus target price of $7.40, suggesting a potential upside of 230.36%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Mereo BioPharma Group 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57 Which has preferable earnings and valuation, UNCY or MREO? Unicycive Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive TherapeuticsN/AN/A-$36.73M-$4.12-1.21Mereo BioPharma Group$10M35.62-$43.25M-$0.07-32.00 Which has more volatility & risk, UNCY or MREO? Unicycive Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Do institutionals & insiders have more ownership in UNCY or MREO? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMereo BioPharma Group beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.19M$2.64B$6.14B$10.55BDividend YieldN/A57.79%5.72%4.84%P/E Ratio-1.2123.8629.4727.34Price / SalesN/A726.44567.66227.59Price / CashN/A27.2425.8230.35Price / Book6.945.4612.436.69Net Income-$36.73M$33.06M$3.32B$276.46M7 Day Performance9.65%1.45%1.84%-0.08%1 Month Performance26.26%10.14%8.84%3.93%1 Year Performance15.02%-2.58%63.12%33.89% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.6728 of 5 stars$5.00+6.2%$57.00+1,040.0%+16.6%$83.19MN/A-1.219MREOMereo BioPharma Group1.9957 of 5 stars$2.00+2.0%$7.40+270.0%-51.5%$311.64M$10M-28.5740NMRANeumora Therapeutics2.0193 of 5 stars$1.86-1.6%$7.14+284.0%-89.0%$306.08MN/A-1.18108ALECAlector4.065 of 5 stars$3.04+0.7%$4.17+37.1%-33.7%$305.66M$100.56M-2.62270Positive NewsGALTGalectin Therapeutics1.2772 of 5 stars$5.10+8.1%$6.00+17.6%+90.6%$302.36MN/A-7.979News CoverageGap UpSCPHscPharmaceuticals3.7804 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330TECXTectonic Therapeutic2.3379 of 5 stars$16.09+0.4%$80.29+399.0%-49.1%$299.77MN/A-3.98120News CoverageAnalyst ForecastACBAurora Cannabis0.5431 of 5 stars$5.40+1.9%N/A-4.7%$297.98M$246.72M-28.421,130JBIOJade Biosciences2.0202 of 5 stars$9.09+0.1%$19.00+109.0%N/A$296.25MN/A-0.3020Gap DownIMMPPrima BioMed0.7316 of 5 stars$1.99-1.0%$7.00+251.8%+2.5%$295.86M$6.69M0.002,021News CoverageKYTXKyverna Therapeutics2.3721 of 5 stars$6.93+4.5%$19.00+174.2%+33.0%$286.72M$7.03M-1.8896Gap Up Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Neumora Therapeutics Alternatives Alector Alternatives Galectin Therapeutics Alternatives scPharmaceuticals Alternatives Tectonic Therapeutic Alternatives Aurora Cannabis Alternatives Jade Biosciences Alternatives Prima BioMed Alternatives Kyverna Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
